Los Angeles Capital Management
AVDL

Los Angeles Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Los Angeles Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,331
Closed -$1.42M – 2404
2025
Q4 		$1.42M Sell
75,331
-9,164
-11% -$178K ﹤0.01% 531
2025
Q3 		$1.29M Buy
84,495
+5,381
+7% +$70K ﹤0.01% 631
2025
Q2 		$700K Buy
+79,114
New +$695K ﹤0.01% 760

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Los Angeles Capital Management's AVDL Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 75,331 shares — an estimated $1.42M sold.

Los Angeles Capital Management first reported a position in AVDL in Q2 2025 and held it in 3 quarters. The position peaked at $1.42M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 75,331 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.42M.
  • Los Angeles Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Los Angeles Capital Management's Avadel Pharmaceuticals position peaked at $1.42M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.